Document is current
Any future updates will be listed below
-
Authors
Fornaro, Michele https://orcid.org/0000-0002-9647-0853
Caiazza, Claudio
Solini, Niccolò
De Prisco, Michele
Billeci, Martina
Vannini, Martina
Shorr, Risa
Caiolo, Stefano
Lussignoli, Marialaura
Siskind, Dan https://orcid.org/0000-0002-2072-9216
Pigato, Giorgio
Barone, Annarita
Sambataro, Fabio
de Bartolomeis, Andrea
Correll, Christoph U.
Solmi, Marco https://orcid.org/0000-0003-4877-7233
- License Information
-
More Information
Article History
Received: 1 December 2022
Revised: 30 August 2023
Accepted: 11 September 2023
First Online: 11 October 2023
Competing interests
: CUC reported receiving personal fees from Alkermes plc, Allergan plc, Angelini Pharma, Gedeon Richter, Gerson Lehrman Group, Intra-Cellular Therapies, Inc, Janssen Pharmaceutica/Johnson&Johnson, LB Pharma International BV,H Lundbeck A/S, MedAvante-ProPhase, Medscape, Neurocrine Biosciences, Noven Pharmaceuticals, Inc, Otsuka Pharmaceutical Co, Inc, Pfizer, Inc, Recordati, Rovi, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Inc, Supernus Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals, Acadia Pharmaceuticals, Inc, Axsome Therapeutics, Inc, Indivior, Merck&Co, Mylan NV, MedInCell, and Karuna Therapeutics and grants from Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Berlin Institute of Health, the National Institute of Mental Health, Patient Centered Outcomes Research Institute, and the Thrasher Foundation outside the submitted work; receiving royalties from UpToDate; and holding stock options in LB Pharma. No other disclosures were reported. AdB has received research support from Janssen, Lundbeck, and Otsuka and lecture fees for educational meeting from Chiesi, Lundbeck, Roche, Sunovion, Viatris, Recordati, Angelini and Takeda; he has served on advisory boards for Eli Lilly, Jansen, Lundbeck, Otsuka, Roche, and Takeda, Chiesi, Recordati, Angelini, Vitria. MS has received honoraria/has been a consultant for Angelini, Lundbeck, and Otsuka. MF received honoraria from the American Society of Clinical Psychopharmacology (ASCP), Angelini, Lundbeck, Bristol Meyer Squibb, and Boehringer-Ingelheim for his speaker activities. GP has received research grants and/or has been a consultant for, and/or has been a speaker for: Angelini, Lundbeck, Janssen, Otsuka, Pfizer, Roche, Eisai. DS is funded in part by an NHMRC EL2 Fellowship GNT1194635. FS has received honoraria/has been a consultant for Janssen (past five years). The other authors report no conflict of interest.
